Detection of breast cancer in an FDG-PET cancer screening program: results of a nationwide Japanese survey.

abstract：AIM:Our study was to investigate the heterogeneity of estrogen receptor (ER) expression among tumor sites by using fluorine-18 ((18)F) fluoroestradiol (FES) positron-emission tomography-computed tomography (PET-CT) imaging. METHODS:Thirty-two breast cancer patients underwent both (18)F-FES and (18)F fluorodeoxyglucose...

journal_title：Clinical breast cancer

authors： Yang Z,Sun Y,Zhang Y,Xue J,Wang M,Shi W,Zhu B,Hu S,Yao Z,Pan H,Zhang Y

更新日期：2013-10-01 00:00:00

abstract：:Sentinel lymph node dissection (SLND) is a minimally invasive technique to stage axillary lymph nodes in breast cancer. The complications associated with SLND are minimal, especially when compared to routine axillary lymph node dissection (ALND), and it can be performed with an overall identification rate of greater t...

journal_title：Clinical breast cancer

authors： Kelemen PR

更新日期：2000-07-01 00:00:00

abstract：BACKGROUND:Irinotecan has a 20% to 25% response rate (RR) in patients with previously treated metastatic breast cancer (MBC). Epidermal growth factor receptor (EGFR) is overexpressed in some MBC, especially in triple-negative breast cancer (TNBC). Cetuximab is a monoclonal antibody against EGFR with additive preclinica...

journal_title：Clinical breast cancer

authors： Crozier JA,Advani PP,LaPlant B,Hobday T,Jaslowski AJ,Moreno-Aspitia A,Perez EA

更新日期：2016-02-01 00:00:00

abstract：:The androgen receptor (AR) is increasingly considered as a potential biomarker for breast cancer. Nevertheless, the prognostic value of AR expression in patients with triple negative breast cancer (TNBC) remains controversial. Therefore, in this meta-analysis, we investigated AR expression and its impact on survival o...

journal_title：Clinical breast cancer

authors： Xu M,Yuan Y,Yan P,Jiang J,Ma P,Niu X,Ma S,Cai H,Yang K

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:Adjuvant trastuzumab improves relapse-free survival in HER2-overexpressing breast cancer but is associated with cardiac toxicity. This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly p...

journal_title：Clinical breast cancer

authors： Kelly H,Kimmick G,Dees EC,Collichio F,Gatti L,Sawyer L,Ivanova A,Dressler L,Graham ML,Carey LA

更新日期：2006-08-01 00:00:00

abstract：PURPOSE:This multicenter phase II trial evaluated the efficacy and safety of weekly nanoparticle albumin-bound paclitaxel with carboplatin and weekly trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer (MBC). PATIENTS AND METHODS:We treated 32 patients who had measurable MBC t...

journal_title：Clinical breast cancer

authors： Conlin AK,Seidman AD,Bach A,Lake D,Dickler M,D'Andrea G,Traina T,Danso M,Brufsky AM,Saleh M,Clawson A,Hudis CA

更新日期：2010-08-01 00:00:00

abstract：:Women with germline mutations in BRCA1 or BRCA2 are known to be at substantially elevated risk for breast cancer. With increasing acceptance of genetic testing, significant numbers of mutation carriers are being identified, but evidence-based guidelines for the management of women at hereditary risk are lacking. This ...

journal_title：Clinical breast cancer

authors： Robson M

更新日期：2004-10-01 00:00:00

abstract：:Breast cancer is the most common cancer affecting women, causing 29% of all female cancers and afflicting 14% of all female cancer-related deaths worldwide. It remains a significant clinical, psychological, and financial burden. Exercise has been suggested to reduce cancer recurrence and cancer-related mortality from ...

journal_title：Clinical breast cancer

authors： Kapila AK,Hamdi M,Patel A

更新日期：2018-10-01 00:00:00

abstract：PURPOSE:The purpose of this study is to determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC) and to search for a correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. PATIENTS AND ME...

journal_title：Clinical breast cancer

authors： Yerushalmi R,Hayes MM,Gelmon KA,Chia S,Bajdik C,Norris B,Speers C,Hassell P,O'Reilly SE,Allan S,Shenkier TN

更新日期：2009-08-01 00:00:00

abstract：:Prostate adenocarcinoma can manifest as a fairly indolent tumor or as a very aggressive cancer with significant invasive and metastatic potential. Common metastatic sites include bone, liver, lymph nodes, and adrenal glands. Dermatologic manifestations are rare. We present a case of a man who presented with breast ski...

journal_title：Clinical breast cancer

authors： Njiaju UO,Truica CI

更新日期：2010-02-01 00:00:00

abstract：BACKGROUND:This study was performed to determine whether the use of ovulation induction drugs in treatment of infertility have a significant effect on the risk of breast cancer. PATIENTS AND METHODS:This case control study (928 cases, 928 controls), was performed in the gynecology and oncology clinics of Shahid Behesh...

journal_title：Clinical breast cancer

authors： Taheripanah R,Balash F,Anbiaee R,Mahmoodi M,Akbari Sene A

更新日期：2018-10-01 00:00:00

abstract：INTRODUCTION:Implant-sparing mastectomy (ISM) is a skin-sparing mastectomy that preserves a retropectoral implant and potentially eliminates the need for tissue expansion or complex reconstruction. This study aimed to determine oncologic and surgical outcomes and reconstructive patterns in patients undergoing ISM. PAT...

journal_title：Clinical breast cancer

authors： Burke EE,Laronga C,Sun W,DeBiase S,Naqvi SMH,Fridley B,Czerniecki BJ,Hoover SJ,Khakpour N,Kiluk JV,Lee MC

更新日期：2020-02-01 00:00:00

abstract：:Overexpression of the p185/HER2 protein is seen in 20%-25% of primary breast cancers and is associated with poor prognosis. Recent phase II and III clinical trials demonstrate that trastuzumab is active against breast tumors, both as a single agent and in combination with chemotherapy. In patients with HER2-overexpres...

journal_title：Clinical breast cancer

authors： Pegram MD,O'Callaghan C

更新日期：2001-10-01 00:00:00

abstract：INTRODUCTION:Axillary lymph node dissection (ALND) is currently the recommended procedure in patients with tumor-positive sentinel lymph node biopsy (SLNB). A significant proportion of patients with positive SLNs will not have any additional metastases in nonsentinel lymph nodes (NSLNs). Predictive nomograms could iden...

journal_title：Clinical breast cancer

authors： Nadeem RM,Gudur LD,Saidan ZA

更新日期：2014-08-01 00:00:00

abstract：:Breast-conserving therapy (BCT) consists of segmental mastectomy followed by postoperative radiation therapy (RT) to the whole breast. At least 6 prospective randomized trials have proven the equivalence of BCT to mastectomy. However, BCT remains underused and, most importantly, a sizable proportion of patients with i...

journal_title：Clinical breast cancer

authors： Truong MT,Hirsch AE,Formenti SC

更新日期：2003-10-01 00:00:00

abstract：BACKGROUND:Luminal-type breast cancers are the most abundant subtype. Endocrine therapies targeting estrogen receptor (ER) or estradiol (E2) synthesis have achieved marked improvement in disease-free and overall survival of ER-positive cancers. However, approximately one-third of these cancers are poorly responsive to ...

journal_title：Clinical breast cancer

authors： Ito T,Sato N,Yamaguchi Y,Tazawa C,Moriya T,Hirakawa H,Hayashi S

更新日期：2015-04-01 00:00:00

abstract：INTRODUCTION:The purpose of this study was to evaluate the added value of breast magnetic resonance imaging (MRI) in preoperative diagnosis of ductal carcinoma in situ (DCIS). We reviewed our institution database of 3499 consecutive patients treated for breast cancer. PATIENTS AND METHODS:A total of 362 patients with ...

journal_title：Clinical breast cancer

authors： Petrillo A,Fusco R,Petrillo M,Triunfo F,Filice S,Vallone P,Setola SV,Rubulotta M,Di Bonito M,Rinaldo M,D'Aiuto M,Brunetti A

更新日期：2017-06-01 00:00:00

abstract：:The perinatal period, childhood, and adolescence are important intervals for breast cancer risk development. Endogenous estrogen exposure is thought to be highest in utero, and exposure to estrogens throughout life plays an important role in increasing breast cancer risk. Some evidence suggests that breast tissue is n...

journal_title：Clinical breast cancer

authors： Ruder EH,Dorgan JF,Kranz S,Kris-Etherton PM,Hartman TJ

更新日期：2008-08-01 00:00:00

abstract：:Breast cancer stem cells (BCSCs), characterized by the CD44(+)/CD24(-/low) marker, are attributed with features that are demonstrated by the disease itself, such as growth of tumor, recurrence, metastases, and multiple drug resistance. This review concerns the emergence and expediency of BCSCs in treating relapse and ...

journal_title：Clinical breast cancer

authors： Gangopadhyay S,Nandy A,Hor P,Mukhopadhyay A

更新日期：2013-02-01 00:00:00

abstract：BACKGROUND:The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS:Eight hundred women were i...

journal_title：Clinical breast cancer

authors： Choi WJ,Cha JH,Kim HH,Shin HJ,Chae EY

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Studies have shown that young patients with early-stage breast cancer (BC) are increasingly undergoing mastectomy instead of breast-conserving therapy (BCT) consisting of lumpectomy and radiation. We examined the difference in outcomes in young women (aged < 40 years) who had undergone BCT versus mastectomy....

journal_title：Clinical breast cancer

authors： Ye JC,Yan W,Christos PJ,Nori D,Ravi A

更新日期：2015-10-01 00:00:00

abstract：BACKGROUND:The inexpensive prediction of the characteristics of BRCA-mutated breast cancer as "BRCAness" using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness with the clinicopathologic features, including a family history (...

journal_title：Clinical breast cancer

authors： Mori H,Kubo M,Kai M,Velasquez VV,Kurata K,Yamada M,Okido M,Kuroki S,Oda Y,Nakamura M

更新日期：2018-10-01 00:00:00

abstract：:Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic, immunohistochemical, and molecular features. Resistance to systemic therapies, whether chemotherapy or hormonal therapy, is among its main characteristics, which in turn explains the poor prognosis and renders its manage...

journal_title：Clinical breast cancer

authors： Tzanninis IG,Kotteas EA,Ntanasis-Stathopoulos I,Kontogianni P,Fotopoulos G

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Recent studies have shown that breast cancer detected by screening has a more favorable prognosis than interval breast cancer. To further understand the biologic significance of this finding, we investigated the association of disease recurrence, local and distant, with the method of detection of the primary...

journal_title：Clinical breast cancer

authors： Tchou J,Greshock J,Bergey MR,Sonnad SS,Sargen M,Weinstein S,Czerniecki BJ,Boraas M,Fraker DL,Rosato E,Fox K,Weber B,Solin LJ

更新日期：2008-04-01 00:00:00

abstract：INTRODUCTION:Dose-dense therapies have had a major effect on reducing toxicity and improving outcomes in breast cancer. A combination of TC every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to delive...

journal_title：Clinical breast cancer

authors： Burkard ME,Wisinski KB,Njiaju UO,Donohue S,Hegeman R,Stella A,Mansky P,Shah V,Goggins T,Qamar R,Dietrich L,Kim K,Traynor AM,Tevaarwerk AJ

更新日期：2014-06-01 00:00:00

abstract：:This article attempts to provide the reader with a complete overview of topoisomerase (topo) II alpha as a marker for predicting the efficacy of anthracyclines in patients with breast cancer. In the first section of this article, in vitro data supporting the predictive value of topo II alpha are reviewed. Interestingl...

journal_title：Clinical breast cancer

authors： Di Leo A,Isola J

更新日期：2003-08-01 00:00:00

abstract：BACKGROUND:We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. MATERIALS AND METHODS:This study included the first 50 ...

journal_title：Clinical breast cancer

authors： Chadha M,Vongtama D,Friedmann P,Parris C,Boolbol SK,Woode R,Harrison LB

更新日期：2012-02-01 00:00:00

abstract：:A 40-year-old woman, 6 years after mastectomy, lymph node dissection, and locoregional radiation, presented with hepatic metastases, pruritus, and jaundice. Physical examination revealed uniformly jaundiced skin and no arm lymphedema. Ultrasonography confirmed progressive hepatic metastases with no evidence of intrahe...

journal_title：Clinical breast cancer

authors： Tsang RY,Mackey JR

更新日期：2007-12-01 00:00:00

abstract：:Post-breast cancer treatment-related angiosarcomas were first observed in lymphedematous extremities after mastectomy and are now being reported with increasing frequency after lumpectomy and radiation. A case history is presented of a BRCA2 carrier who had a postmastectomy chest wall angiosarcoma but had neither ther...

journal_title：Clinical breast cancer

authors： West JG,Weitzel JN,Tao ML,Carpenter M,West JE,Fanning C

更新日期：2008-12-01 00:00:00

abstract：INTRODUCTION:The adjuvant trastuzumab trials largely excluded women with small, node-negative, HER2-positive breast cancers. Accordingly, limited data exist regarding the effect of trastuzumab in the management of these patients. Our aim was to assess the outcomes of, and treatments administered to, women with small (≤...

journal_title：Clinical breast cancer

authors： Tognela A,Beith J,Kiely B,Bastick P,Lynch J,Descallar J,Mok K

更新日期：2015-08-01 00:00:00